Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
A dystonia characterized by autosomal recessive inheritance of progressive dystonia, dysphonia, dysarthria and neck torticollis that has material basis in variation in the chromosome region 20p11.2-q13.12.
Features include very common findings: Dysphonia, Dysarthria, and Generalized dystonia; and common findings: Torticollis and Craniofacial dystonia. 6 total HPO annotations.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Brain and nerves | 5 | Dysphonia, Dysarthria, Focal dystonia |
Biomarker and diagnostic research for torsion dystonia 17 has been reported in the published literature.
Phenotype severity distribution: 3 very common features, 2 common features.
Estimated prevalence: <1 in 1,000,000 (VERY_RARE).
No clinical trials have been registered for torsion dystonia 17.
103 publications have been identified in PubMed for torsion dystonia 17. Research spans Review / Meta-Analysis (37%), Case Report / Case Series (18%), and Epidemiology / Natural History (14%).
Research Type | Count | % of Total |
|---|---|---|
Research summaries | 31 | 37% |
Data assembled from 5 of 12 sources · Last updated Sep 19, 2026, 1:16 AM UTC
Online Mendelian Inheritance in Man
European rare disease database
Genetic and Rare Diseases Info Center
1 |
Craniofacial dystonia |
15 |
18% |
Disease patterns and progression | 12 | 14% |
Clinical study results | 10 | 12% |
Laboratory research | 10 | 12% |
Testing and diagnosis research | 5 | 6% |
Other research | 1 | 1% |
Benn M (2026). [PMID: 30571002](https://pubmed.ncbi.nlm.nih.gov/30571002/). *Unknown Journal*. [Case Report / Case Series]
Altınöz Güney C (2026). [PMID: 41447583](https://pubmed.ncbi.nlm.nih.gov/41447583/). *Cutan Ocul Toxicol*. [Epidemiology / Natural History]
Ahmad I (2026). [PMID: 42177941](https://pubmed.ncbi.nlm.nih.gov/42177941/). *J Pediatr Surg*. [Epidemiology / Natural History]
Alexander CE (2026). [PMID: 40368720](https://pubmed.ncbi.nlm.nih.gov/40368720/). *Eur Urol Focus*. [Review / Meta-Analysis]
Fukui H (2026). [PMID: 41207995](https://pubmed.ncbi.nlm.nih.gov/41207995/). *Jpn J Radiol*. [Review / Meta-Analysis]
Wu MY (2026). [PMID: 41650494](https://pubmed.ncbi.nlm.nih.gov/41650494/). *Clin Radiol*. [Review / Meta-Analysis]
Fang H (2026). [PMID: 41606759](https://pubmed.ncbi.nlm.nih.gov/41606759/). *Eur J Med Res*. [Diagnostic / Biomarker]
Alsabri M (2026). [PMID: 41947044](https://pubmed.ncbi.nlm.nih.gov/41947044/). *Int J Emerg Med*. [Review / Meta-Analysis]
Melhem S (2026). [PMID: 42282487](https://pubmed.ncbi.nlm.nih.gov/42282487/). *J Surg Case Rep*. [Case Report / Case Series]
Capponi S (2026). [PMID: 42086561](https://pubmed.ncbi.nlm.nih.gov/42086561/). *Nat Commun*. [Basic Science / Preclinical]
AI-curated news mentioning torsion dystonia 17
Updated Sep 9, 2026
A case report highlights the correlation between post-operative stun effects captured by local field potentials and temporary symptom relief in an adolescent with dystonia. This finding may provide insights into the mechanisms of symptom management in dystonia patients.
Dystonia Europe emphasizes solidarity and awareness for individuals living with dystonia during Rare Disease Day. The organization continues to advocate for better understanding and support for this condition.
A recent study analyzes the rare variant burden of dystonia-related genes in patients with Parkinson's disease, providing insights into genetic contributions to the condition. This research could inform future therapeutic strategies and genetic testing approaches.
A case report highlights dystonia as an early symptom in a patient with a CYP2U1 gene mutation, expanding the known phenotype of SPG56. This finding may enhance understanding of the disease's clinical presentation.
Vima has secured $100 million in funding to develop an oral drug aimed at treating movement disorders, specifically targeting dystonia and Parkinson's disease. This investment positions Vima to advance its innovative approach to restoring movement control.